

Remarks/Arguments

According to the Office Action mailed on May 11, 2006, Applicants were request to elect, for examination in the present application, one of the following inventions:

Group I: Claims 1-12 and 20, drawn to clone 65 polynucleotides, vectors, and host cells;

Group II: Claims 13-17, 21, 38 and 40, drawn to clone 65 polypeptides;

Group III: Claims 18 and 19, drawn to an antibody that binds a clone 65 polypeptide, and a kit comprising said antibody;

Group IV: Claims 22-34 and 36, drawn to clone 320 polynucleotides, vectors, and host cells;

Group V: Claims 35, 37 and 42, drawn to clone 320 polypeptides;

Group VI: Claims 39 and 41, drawn to antagonists of clone 65 polypeptides;

Group VIII drawn to antagonists of clone 320 polypeptides.


The invention of group II, claims 13-17, 21, 38 and 40 is hereby elected, without traverse.

The present application is believed to be in *prima facie* condition for allowance, and an early action to that effect is respectfully solicited.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 08-1641 (Attorney Docket No.: 39766-0257R1C1).

Respectfully submitted,

Date: July 14, 2006



Ginger R. Dreger
Reg. No. 33, 055

HELLER EHRMAN LLP
Customer No. 25213
275 Middlefield Road
Menlo Park, California 94025
Telephone: (650) 324-7000
Facsimile: (650) 324-0638
SV 2220539 v1